As part of the deal, DKSH will import investigational products, products storage, delivery, return and destruction.
Nordic Bioscience head of Clinical Development Jeppe Ragnar Andersen said the company is happy to work with DKSH Hong Kong.
“Hong Kong has excellent infrastructure in terms of transportation, workforce and legal framework for conducting clinical trials.
The deal is expected to further strengthen DKSH’s market position in healthcare in Hong Kong while contributing incrementally to the group’s overall profitability over time.
Source: Pharmaceutical Business Review